Abiopharma

🔍 Apeiron Investment Group Ltd. (Executive)

Company: Enhanced Group Inc. (ENHA)

Report Date: 2026-08-14

Detailed Transactions and Holdings:

• Acquired 2,120,823 shares of Class A Common Stock (Direct)
  Date: 2026-08-14 | Code: A | equity_swap_involved: false | shares_owned_after: 35,183,635.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2, F3
• Acquired 93,000 shares of Class A Common Stock at $1.7012 per share (Direct)
  Date: 2026-08-18 | Code: P | equity_swap_involved: false | shares_owned_after: 35,276,635.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 1,619,316 shares of Class A Common Stock at $1.66 per share (Direct)
  Date: 2026-08-19 | Code: P | equity_swap_involved: false | shares_owned_after: 36,895,951.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 55,000 shares of Class A Common Stock at $1.6433 per share (Direct)
  Date: 2026-08-19 | Code: P | equity_swap_involved: false | shares_owned_after: 36,950,951.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 2,120,823 shares of Warrants at $3.89 per share (Derivative)
  Date: 2026-08-14 | Code: A | equity_swap_involved: false | shares_owned_after: 5,141,388.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4, F3

Footnotes:

• F1: Represents securities received pursuant to a securities purchase agreement between the Issuer and Apeiron Investment Group Ltd. ("Apeiron"), pursuant to which the Issuer agreed to issue and sell in tranches to Apeiron in a private placement (the "Private Placement") (A) 5,141,388 shares of Class A Common Stock and (B) warrants to purchase 5,141,388 shares of Class A Common Stock (the "Warrants"). The Class A Common Stock and Warrants will be issued separately. The combined purchase price per share of Class A Common Stock and accompanying Warrant is $3.89. On August 14, 2026, the second tranche of the Private Placement closed.
• F2: The total in Column 5 of Table I represents the amount of Class A Common Stock held by the Reporting Persons as of the date of this filing.
• F3: The securities reported herein are held of record by Apeiron, as nominee for Enhanced Holdings LP. Christian Angermayer is the sole voting shareholder of Apeiron, which is the sole shareholder of Enhanced Holdings GP, which is the general partner of Enhanced Holdings LP. As a result, each of the foregoing entities and Mr. Angermayer may be deemed to share beneficial ownership over the securities reported herein. Mr. Angermayer disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
• F4: The Warrants are currently exercisable and have a five-year term, which may be accelerated if the Class A Common Stock trades at or above $20 for at least twenty consecutive trading days.